MultiCell Technologies, Inc. (MCET) Stock Price & Analysis

MultiCell Technologies, Inc. (MCET) Healthcare & Pipeline Overview

MultiCell Technologies, Inc. is a biopharmaceutical entity engaged in developing novel therapeutics for neurological disorders, hepatic disease, cancer, and interventional cardiology. The company's pipeline features a Phase II candidate for MS-related fatigue, preclinical cancer therapies, and a bioabsorbable stent, operating with a small team and leveraging strategic licensing agreements.

What Is the Investment Thesis for MCET?

MultiCell Technologies, Inc. presents an investment profile centered on its early-stage biopharmaceutical pipeline and the potential for significant value creation if its therapeutic candidates achieve clinical success. The company's portfolio includes MCT-125, a Phase II candidate for MS-related fatigue, and preclinical/discovery stage assets like MCT-465 and MCT-485 for cancer, alongside the Ideal BioStent for cardiovascular applications. These assets target substantial markets, offering potential for high returns if they advance through rigorous clinical trials and regulatory approvals. However, the company operates with a notable negative profit margin of -770.7% and a market capitalization of $0.00B, reflecting its pre-commercial stage and significant R&D expenditures. The 100.0% gross margin indicates a current focus on intellectual property development rather than product sales. Key value drivers include successful clinical trial outcomes, potential for new licensing agreements, and the ability to secure further funding to support its extensive development efforts. The inherent risks of biotechnology development, including high failure rates and lengthy timelines, are significant considerations.

Based on FMP financials and quantitative analysis

MCET Key Highlights

MultiCell Technologies, Inc. currently holds a market capitalization of $0.00 billion, indicating a very low public valuation.

• The company reported a profit margin of -770.7%, reflecting substantial operating losses typical for a pre-revenue biopharmaceutical firm heavily invested in research and development.
• A gross margin of 100.0% suggests that the company currently incurs no direct cost of goods sold, consistent with its focus on drug discovery and development rather than commercialized product sales.
• The company's Beta is reported as -35.68, an exceptionally unusual figure that may indicate extremely low trading volume, data anomalies, or a highly inverse relationship to market movements, requiring careful interpretation.
• MultiCell Technologies, Inc. operates with a very lean team, employing just two individuals, which highlights its focused R&D model and potentially outsourced operational aspects.

Who Are MCET's Competitors?

MCET is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MCET's Key Strengths?

Diverse product pipeline addressing multiple therapeutic areas: neurological disorders, oncology, and cardiovascular applications.

• Existing license agreements with major industry players, Corning Incorporated and Pfizer Inc., validating its technology.
• MCT-125 is in Phase II clinical trials, indicating progress beyond early discovery for a key candidate.
• 100.0% gross margin, reflecting a focus on intellectual property development without significant cost of goods sold.

What Are MCET's Weaknesses?

Significant negative profit margin of -770.7%, indicating substantial ongoing losses and high R&D costs.

• Very small operational team of only two employees, which may limit capacity for extensive development and commercialization efforts.
• Product pipeline is largely in early stages (preclinical and discovery), with high inherent risks of failure.
• Market capitalization of $0.00B suggests an extremely low valuation and potential challenges in attracting significant investment.

What Are the Key Risks for MCET?

The company faces significant financial instability, evidenced by a -770.7% profit margin and a $0.00B market cap, indicating substantial losses and a need for continuous capital infusion.

• Its product pipeline is predominantly in early stages (Phase II, preclinical, discovery), carrying inherent high risks of clinical trial failure, regulatory setbacks, and lengthy development timelines.
• MultiCell Technologies operates with only two employees, which may pose operational challenges in managing a diverse pipeline and executing complex clinical development programs effectively.
• The 'OTC Other' listing and 'Unknown' disclosure status severely limit transparency, liquidity, and investor confidence, making it difficult to assess the company's true financial and operational health.
• Intense competition from larger, well-funded biopharmaceutical companies in its target therapeutic areas could hinder market penetration and the ability to secure partnerships or funding.

What Threats Does MCET Face?

• High failure rates inherent in biopharmaceutical clinical trials, potentially leading to significant financial losses.
• Intense competition from larger, well-funded pharmaceutical and medical device companies.
• Challenges in securing sufficient capital to fund lengthy and expensive research and development programs.
• Regulatory hurdles and lengthy approval processes for both drug candidates and medical devices.
• Limited transparency and liquidity risks associated with its OTC Other market classification and unknown disclosure status.

What Are MCET's Competitive Advantages?

• Proprietary drug candidates and medical device technology, including specific dsRNA therapeutics and the Ideal BioStent.
• Specialized focus on challenging therapeutic areas such as MS-related fatigue, specific cancer types, and bioabsorbable stents.
• Existing license agreements with established industry players like Corning Incorporated and Pfizer Inc., validating its intellectual property.
• Early-stage pipeline development in novel therapeutic modalities, potentially offering first-in-class or best-in-class treatments.
• Accumulated scientific expertise and research data in its niche areas of biopharmaceutical and medical device development.

What Does MCET Do?

MultiCell Technologies, Inc., headquartered in Woonsocket, Rhode Island, is a biopharmaceutical company with a foundational history dating back to its establishment in 1962, originally incorporated as Exten Industries, Inc. The company underwent a significant rebranding in April 2004, adopting its current name to better reflect its evolving focus on cellular and molecular technologies. MultiCell Technologies is dedicated to the discovery and development of novel therapeutics and advanced discovery tools, targeting a diverse range of critical medical conditions including neurological disorders, hepatic disease, various forms of cancer, and applications within interventional cardiology and peripheral vessel treatments. Its product portfolio is characterized by several key candidates at different stages of development. These include MCT-125, a therapeutic candidate currently in Phase II clinical trials, specifically designed to address primary multiple sclerosis-related fatigue. In the oncology space, the company is advancing MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate recognized for its potent immune-enhancing properties, intended for the treatment of solid tumor cancers. Additionally, MCT-485 is a discovery-stage dsRNA therapeutic candidate that exhibits tumor cytolytic properties, being explored for its potential in treating various cancers. Beyond drug development, MultiCell Technologies is also involved in the medical device sector with Ideal BioStent, a bioabsorbable stent designed for use in interventional cardiology and peripheral vessel applications. The company has strategically secured license agreements with prominent industry players, Corning Incorporated and Pfizer Inc., which underscore its collaborative approach to research and development. Operating with a lean structure of two employees, MultiCell Technologies maintains a focused approach on its specialized therapeutic areas.

What Products and Services Does MCET Offer?

• Develops novel therapeutics for neurological disorders, including a Phase II candidate for multiple sclerosis-related fatigue.
• Engages in the discovery and preclinical development of synthetic double-stranded RNA (dsRNA) therapeutics for solid tumor cancers.
• Researches discovery-stage dsRNA therapeutic candidates with tumor cytolytic properties for various cancer treatments.
• Designs and develops bioabsorbable stents for use in interventional cardiology and peripheral vessel applications.
• Holds license agreements with Corning Incorporated and Pfizer Inc., indicating collaborations on its intellectual property.
• Focuses on a pipeline of early-stage biopharmaceutical assets and medical devices.
• Operates as a research and development-centric biopharmaceutical company.

How Does MCET Make Money?

• Primarily focused on research and development (R&D) of novel drug candidates and medical devices.
• Aims to advance its product pipeline through preclinical and clinical trial stages to demonstrate safety and efficacy.
• Seeks to monetize its intellectual property through licensing agreements with larger pharmaceutical or medical device companies.
• Potential future revenue generation from direct sales of approved pharmaceutical products or medical devices.
• Relies on securing funding, potentially through equity financing or partnerships, to support its extensive R&D activities.

What Industry Does MCET Operate In?

MultiCell Technologies, Inc. operates within the highly specialized and capital-intensive biotechnology industry, a sector characterized by long development cycles, significant regulatory hurdles, and high-risk, high-reward potential. The company's focus areas—neurological disorders, oncology, hepatic disease, and interventional cardiology—represent large and growing markets with substantial unmet medical needs. MultiCell Technologies positions itself as an innovator in these fields, developing novel therapeutics and discovery tools. The competitive landscape is intense, featuring both large pharmaceutical companies with extensive resources and numerous smaller biotech firms vying for breakthroughs. MultiCell Technologies, with its early-stage pipeline and limited employee base, faces the challenge of advancing its candidates against established players, relying on the unique potential of its specific drug mechanisms and stent technology to carve out a niche.

Who Are MCET's Key Customers?

• Patients suffering from neurological disorders, particularly multiple sclerosis-related fatigue.
• Patients diagnosed with solid tumor cancers and other forms of cancer.
• Patients requiring interventional cardiology or peripheral vessel procedures who could benefit from bioabsorbable stents.
• Pharmaceutical companies and medical device manufacturers seeking to license or acquire novel therapeutic candidates or technologies.
• Healthcare providers and hospitals that would prescribe or utilize the company's approved products.

Return on equity for MultiCell Technologies, Inc. stands at 164.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching.

Company Profile

MultiCell Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Woonsocket, US. The company is led by CEO W. Gerald Newmin. MCET has traded publicly since 2000.

MultiCell Technologies, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

12 transactions · 1 purchases, 0 sales, 11 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

MCET Financials

MCET Latest News

No recent news available for MCET.

MCET Analyst Consensus

MCET MoonshotScore

MultiCell Technologies, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources